{"title":"A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis.","authors":"Guanghan Wang, Xiaojing Hu, Shixin Han, Meijuan Zhou","doi":"10.1080/09546634.2024.2366535","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Bullous pemphigoid induced by secukinumab in treatment of psoriasis is rare.</p><p><p><b>Methods:</b> We report a 49-year-old man with psoriasis who developed bullous pemphigoid during treatment with secukinumab.</p><p><p><b>Results:</b> Scattered tense vesicles with itching appeared all over the body after the fourth treatment. Bullous pemphigoid was confirmed by pathological examination and direct immunofluorescence. The patient was treated with topical corticosteroids, oral nicotinamide and minocycline hydrochloride. The lesions of bullous pemphigoid improved significantly after 7 days of treatment.</p><p><p><b>Conclusions:</b> Bullous pemphigoid is a rare adverse event following administration of secukinumab.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2366535"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2024.2366535","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: Bullous pemphigoid induced by secukinumab in treatment of psoriasis is rare.
Methods: We report a 49-year-old man with psoriasis who developed bullous pemphigoid during treatment with secukinumab.
Results: Scattered tense vesicles with itching appeared all over the body after the fourth treatment. Bullous pemphigoid was confirmed by pathological examination and direct immunofluorescence. The patient was treated with topical corticosteroids, oral nicotinamide and minocycline hydrochloride. The lesions of bullous pemphigoid improved significantly after 7 days of treatment.
Conclusions: Bullous pemphigoid is a rare adverse event following administration of secukinumab.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
